Nature Communications (Oct 2021)
Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer
- Paloma Cejas,
- Yingtian Xie,
- Alba Font-Tello,
- Klothilda Lim,
- Sudeepa Syamala,
- Xintao Qiu,
- Alok K. Tewari,
- Neel Shah,
- Holly M. Nguyen,
- Radhika A. Patel,
- Lisha Brown,
- Ilsa Coleman,
- Wenzel M. Hackeng,
- Lodewijk Brosens,
- Koen M. A. Dreijerink,
- Leigh Ellis,
- Sarah Abou Alaiwi,
- Ji-Heui Seo,
- Sylvan Baca,
- Himisha Beltran,
- Francesca Khani,
- Mark Pomerantz,
- Alessandra Dall’Agnese,
- Jett Crowdis,
- Eliezer M. Van Allen,
- Joaquim Bellmunt,
- Colm Morrisey,
- Peter S. Nelson,
- James DeCaprio,
- Anna Farago,
- Nicholas Dyson,
- Benjamin Drapkin,
- X. Shirley Liu,
- Matthew Freedman,
- Michael C. Haffner,
- Eva Corey,
- Myles Brown,
- Henry W. Long
Affiliations
- Paloma Cejas
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- Yingtian Xie
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- Alba Font-Tello
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- Klothilda Lim
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- Sudeepa Syamala
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- Xintao Qiu
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- Alok K. Tewari
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- Neel Shah
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- Holly M. Nguyen
- Department of Urology, University of Washington
- Radhika A. Patel
- Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center
- Lisha Brown
- Department of Urology, University of Washington
- Ilsa Coleman
- Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center
- Wenzel M. Hackeng
- Department of Pathology, University Medical Center Utrecht, Utrecht University
- Lodewijk Brosens
- Department of Pathology, University Medical Center Utrecht, Utrecht University
- Koen M. A. Dreijerink
- Department of Endocrinology, Amsterdam UMC
- Leigh Ellis
- Broad Institute of MIT and Harvard
- Sarah Abou Alaiwi
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- Ji-Heui Seo
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- Sylvan Baca
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- Himisha Beltran
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- Francesca Khani
- Weill Cornell Medical Center, Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital
- Mark Pomerantz
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- Alessandra Dall’Agnese
- Whitehead Institute for Biomedical Research
- Jett Crowdis
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- Eliezer M. Van Allen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- Joaquim Bellmunt
- Beth Israel Deaconess Medical Center and PSMAR-IMIM Lab. Harvard Medical School
- Colm Morrisey
- Department of Urology, University of Washington
- Peter S. Nelson
- Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center
- James DeCaprio
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- Anna Farago
- Massachusetts General Hospital Cancer Center
- Nicholas Dyson
- Massachusetts General Hospital Cancer Center
- Benjamin Drapkin
- Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research
- X. Shirley Liu
- Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
- Matthew Freedman
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- Michael C. Haffner
- Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center
- Eva Corey
- Department of Urology, University of Washington
- Myles Brown
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- Henry W. Long
- Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School
- DOI
- https://doi.org/10.1038/s41467-021-26042-z
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 11
Abstract
Neuroendocrine carcinomas (NECs) arise from different anatomic sites, but have similar histological and clinical features. Here, the authors show that the epigenetic landscape of a range of NECs converges towards a common epigenetic state, while distinct subtypes occur within neuroendocrine prostate cancer contributing to intratumor heterogeneity in clinical samples.
